Chronic Lymphocytic Leukemia

O'Brien Covers Evolution of Long-Term Data With Ibrutinib in CLL Landscape

February 15, 2018

Clinical Articles

Susan O’Brien, MD, discusses the tremendous impact that has been seen with ibrutinib following the long-term follow-up of the RESONATE studies and highlights where this regimen is headed in the future of treatment for patients with CLL.

Emerging Treatment Strategies in CLL

February 14, 2018

Clinical Articles

Prospects for patients with chronic lymphocytic leukemia have improved with the use of targeted agents such as ibrutinib; however, complete remissions are rare, and treatment options for patients relapsing after treatment with ibrutinib remain limited.

Factors Affecting Prognosis and Treatment in CLL

February 15, 2018

Clinical Articles

Based on improved insight into chronic lymphocytic leukemia biology and pathophysiology, approaches to identify patients who are at higher risk for disease progression have been refined, as have strategies to select therapies that maximize treatment outcomes due to their selectivity for distinctive phenotypic or physiological features of the respective CLL cells.

Current Treatment Strategies in CLL

February 15, 2018

Clinical Articles

The clinical course of chronic lymphocytic leukemia is highly variable, and a subset of patients may never need clinical intervention. However, most patients will eventually require treatment during their disease.

Current Approaches to Diagnosis and Risk Stratification in CLL

February 13, 2018

Clinical Articles

Recent years have seen major advances in diagnostic approaches in CLL, and disease assessment may now include analysis of multiple genetic mutations in addition to recurrent cytogenetic changes. Furthermore, with the development of novel treatment approaches, the significance of prognostic markers is shifting.